

Group V ORIGENES-SO

IDENTIFYING DATA

The patient is P.D,


- 77 y/o
- Male
- Filipino
- Roman Catholic
- Sta. Ana, Manila
- 1st admission in UERM Memorial Hospital
- Date of Admission: June 17, 2011

CHIEF COMPLAINT



DIFFICULTY OF BREATHING

6 days duration



PERTINENT NEGATIVES

- Fever
- Chest pain
- Clubbing
- Edema
- Orthopnea

PAST MEDICAL HISTORY

- Pneumonia last June 2010, treated
- PTB diagnosed last March 2011 at a health center, on anti-Koch's medication for 4 months, unrecalled dosage and drug component, good compliance
- Hypertension diagnosed last 2009, maintained on Felodipine 10mg OD (highest BP at 160/100) with poor compliance, with no regular check-ups. Last check-up was unrecalled
- MVA 20 years ago, no chest and lung injury

No history of any surgery

FAMILY & SOCIAL HISTORY



 No family history of Asthma, Cancer and Diabetes.

 Smoker with 30 pack years, occasional alcoholic beverage drinker

REVIEW OF SYSTEMS

 (+) loss of appetite associated with undocumented weight loss

• (+) wears glasses, unrecalled grade

(-) paroxysmal norturnal dyspnea

(-) easy fatigability

PHYSICAL EXAM

| General Survey | Ectomorph, acutely ill, speaks in sentences, not in cardiorespiratory distress | | | |
|-----------------|--|--|--|--|
| Vital Signs | 160/90 >90>18>36.9 | | | |
| HEENT | Anicteric sclerae, pink palpebral conjunctivae, no | | | |
| | tonsillopharyngeal congestion, no cervical | | | |
| | lymphadenopathies, prominent neck veins | | | |
| Chest and Lungs | Chest lag left, decreased tactile fremitus on the left | | | |
| | lung field, hyperresonance on the left lung field, | | | |
| | decreased breath sounds on the left lung field, no | | | |
| | wheezes, no crackles | | | |
| Heart | Adynamic precordium, normal rate and regular | | | |
| | rhythm, distinct S1 and S2, PMI at 5th ICS LMCL, no | | | |
| | murmurs | | | |
| Abdomen | Flat, normoactive bowel sounds, soft abdomen, | | | |
| | tympanitic, non-tender, no masses | | | |
| Extremities | Full and equal pulses, no edema, no cyanosis, no | | | |
| | clubbing | | | |

SALIENT FEATURES

- 77 year old male
- Smoker, 30 pack years
- Hypertensive
- History of PTB and Pneumonia
- Difficulty of breathing of 6 days
- Dyspnea on exertion
- Productive cough with whitish, purulent discharge
- Perioral cyanosis

SALIENT FEATURES

• BP = 160/90

 Chest lag left, decreased tactile fremitus on the left lung field, hyperresonance on the left lung field, decreased breath sounds on the left lung field

DIFFERENTIAL DIAGNOSES



- 1. Pleural Effusion
- 2. COPD in acute exacerbation
- 3. Pneumonia
- 4. Congestive Heart Failure

Differential Diagnosis Pleural effusion

| Rule In | Rule Out |
|--|---|
| Diagnosed case of COPD and PTB Presence of intermittent dyspnea described as inability to get enough air Decreased breath sounds on auscultation | Absence of chest pain Patient was not tachypneic No orthopnea No increased resonance of voice sounds No history of surgery, trauma, or immobility |

Differential Diagnosis Chronic Obstructive Pulmonary disease in acute exacerbation

| Rule In | Rule Out |
|---|---|
| Age of patient (77 years old) History of PTB and Pneumonia Perioral Cyanosis Productive cough Dyspnea especially on exertion 30 pack years smoking | No fatigue and weakness No wheezing No chest tightness No use of accessory muscles No tachypnea No fever No Malaise No change in sputum color or amount No signs of fluid retention |

Differential Diagnosis Pneumonia

| Rule In | Rule Out |
|---|--|
| Increase risk due to patient's age, history of smoking and COPD Productive cough with whitish mucoid sputum. Decrease tactile fremitus on left lung field. Decrease breath sound | Patient was afebrile No tachycardia and tachypnea, no use of accessory muscles of respiration. No crackles on auscultation |
| | |

Differential Diagnosis Congestive Heart Failure

| Rule In | Rule Out | |
|--|--|--|
| Age of patient (77 years old) Higher in men Presence of Hypertension Presence of Dyspnea on exertion With Weight loss Central cyanosis | No fatigue No orthopnea No paroxysmal nocturnal dyspnea No Cheyne-Stokes Respiration No anorexia, nausea, and early satiety associated with abdominal pain and fullness No right-upper quadrant pain No rales PMI of patient at 5th ICS LMCL No S3, no murmurs of mitral and tricuspid regurgitation No hepatomegaly, ascites, jaundice, peripheral edema | |

APPROACH TO DYSPNEA





Physical Examination



General Appearance: Speak in full sentences?

Accessory muscles? Color?

Vital Signs: Tachypnea? Pulsus Paradoxus?

Oximetry-evidence of desaturation?

Cardiac exam: JVP elevated? Precordial impulse?

Gallop? Murmur?

Extremitites: Edema? Cyanosis?

At this point, diagnosis may be evident—if not, proceed to further evaluation

Chest radiograph
Assess cardiac size, evidence of CHF
Assess for hyperinflation
Assess for pneumonia, interstitial lung
disease, pleural effusions


Suspect low cardiac output, myocardial ischemia, or pulmonary vascular disease


Suspect respiratory pump or gas exchange abnormality

Suspect high cardiac output


CHEST X-RAY

Fibrotic opacities in both upper lungs





03.22.2011 06.18.2011



ECG and echocardiogram assess left ventricular function and pulmonary artery pressure

Pulmonary function testing- if diffusing capacity reduced, consider CT angiogram to assess for interstitial lung disease and pulmonary embolism

Hematocrit, thyroid function tests



ECG




ECG

- Sinus Rhythm
- ❖ Heart Rate: 95-100 bpm
- ❖ 90° axis
- Right Atrial Enlargement
- ❖ Poor R wave progression
- Non-specific T wave changes
- No hypertrophy, infarct, injury

ABG

| рН | 7.44 | Total CO ₂ | 36.10 |
|--------------------|--------|-----------------------|-------|
| pCO ₂ | 50 ↑ | FIO2 | 2 LPM |
| pO_2 | 90 | Temp | 36 |
| HCO ₃ | 34.5 ↑ | RR | 21 |
| BE | 10.2 ↑ | Po2 | 47 |
| O ₂ sat | 98 | PO2 | 0.5 |



Source: Fauci AS, Kasper DL, Braunwald E, Hauser SL, Longo DL, Jameson JL, Loscalzo J Harrison's Principles of Internal Medicine, 17th Edition: http://www.accessmedicine.com
Copyright © The McGraw-Hill Companies, Inc. All rights reserved.

DIAGNOSTIC PROCEDURES

| CBC | 06.18.2011 | |
|----------------|---------------|--|
| Hgb | 144 | |
| Hct | 42 | |
| RBC | 4.8 | |
| WBC | 9.6 | |
| Neutrophils | 80 | |
| Lymphocytes | 20 | |
| Platelets | 302 | |
| RBC Morphology | Normochromic, | |
| | Normocytic | |

| ELECTROLYTES | 06.18.2011 | |
|--------------|------------|--|
| Sodium | 140 | |
| Potassium | 3.8 | |

DIAGNOSTIC PROCEDURES

| BLOOD CHEMISTRY | 06.18.2011 |
|------------------------|------------|
| Creatinine | 81 |

| OTHERS | 06.18.2011 |
|---------------|------------|
| Bleeding Time | 2′30″ |
| Clotting Time | 12′30″ |


DIAGNOSTIC PROCEDURES

| AFB (06.19.2011) | | | |
|----------------------|--------------|----------|----------|
| Specimen | 1 | 2 | 3 |
| Visual Appearance | Mucosalivary | Salivary | Salivary |
| Reading | 0 | 0 | 0 |
| Lab Diagnosis | | Negative | |

| CHEST | TUBE | DRAIN | I CS |
|---------|-------------|-------|------|
| (06.24. | 2011 | | |

Heavy growth of Acinetobacter spp.

PRIMARY IMPRESSION



SPONTANEOUS PNEUMOTHORAX


PRIMARY (PSP)

- (-) Underlying pulmonary pathology
- 6x more common in Men
- Age: 30-40's
- History of Smoking

SECONDARY (SSP)

- √ (+) Underlying pulmonary pathology
- √ (COPD: most common cause)
- √ 3x more common in Men
- ✓ Age: 60's
- ✓ History of Smoking

PATHOPHYSIOLOGY



MANIFESTATIONS

- PleuriticChest Pain
- Tachycardia
- Hypoxia (Cyanosis)
- Malaise

- Sudden onset of intense dyspnea
- Tachypnea
- Shortness of breath

PHYSICAL EXAMINATION

- ✓ Decreased breath sound
- ✓ Decreased tactile fremitus
- √ Hyperresonance of affected lung field
- ✓ Tachypnea
- ✓ Asymmetrical chest expansion

FINAL DIAGNOSIS



SECONDARY SPONTANEOUS PNEUMOTHORAX

secondary to COPD and PTB

Hypertension Stage I, uncontrolled

TREATMENT & MANAGEMENT

Oxygen Supplement: this has been shown to speed resolution of the pneumothorax

Chest Tube Thoracostomy: the most definitive initial treatment of a pneumothorax


- procedure of choice
- inserted at the "safe zone"

Needle Aspiration

Pleurodesis

Calculating Interpleural Distance

Interpleural distance = A+B+C 3



From: Webb, WR and CB Higgins, 2005. Thoracic Imaging: Pulmonary and Cardiovascular Radiology. USA: Lippincott William & Wilkins. p807

Using the formula in calculating for the interpleural distance:


A= 55 mm

B= 35 mm

C=30 mm

(55+35+30)/3 =

40 mm



Estimating the size of a Pneumothorax

| AVERAGE INTERPLEURAL DISTANCE (mm) | Percent Pneumothorax | |
|------------------------------------|----------------------|----------------|
| | Upright film | Supine film |
| 10 | 14% | 19% |
| 20 | 23% | 29% |
| 30 | 32% | 39% |
| 40 | 40% | 49% |
| 50 | 49% | 59% |

From: Webb, WR and CB Higgins,2005. Thoracic Imaging: Pulmonary and Cardiovascular Radiology. USA: Lippincott William & Wilkins. p807

Management of Spontaneous Secondary Pneumothorax

American College of Chest Physicians Guidelines

 Recommends chest tube insertion for all patients and pleurodesis with the first episode of a secondary spontaneous pneumothorax to prevent a recurrence. Medical thoracoscopy or video-assisted thoracoscopic surgery (VATS) as the primary procedure, and a limited axillary thoracotomy with pleural abrasion as a secondary approach to prevent recurrence.


Management of Spontaneous Secondary Pneumothorax

British Thoracic Society Guidelines 2003

 Simple aspiration is less likely to succed in secondary pneumothoraces and is only recommended as an initial treatment in small (<2cm) pneumothoraces in minimally breathless patients under the age of 50 years. If simple aspiration or catheter aspiration drainage of any pneumothorax is unsuccessful in controlling symptoms, then an intercostal tube should be inserted. Intercostal tube drainage is recommended in secondary pneumothorax except in patients who are not breathless an have a very small (<1 cm or apical) pneumothorax. Chemical pleurodesis can control difficult or recurrent pneumothorax but should only be attempted if the patient is either unwilling or unable to undergo surgery. O2 supplementation via nasal cannula at 2Lpm

Closed tube thoracostomy

Tramadol for pain management



Management Problem: COPD

- None of the existing medications for COPD have been shown to modify the long-term decline in lung function that is the hallmark of this disease.
- Pharmacotherapy for COPD is used to decrease symptoms and/or exacerbations.
- Bronchodilator medications are central to the symptomatic management of COPD

Management of COPD

The patient was treated based on Stage IV: Very Severe COPD where the symptoms of cough and sputum production continue, dsypnea worsens and additional symptoms heralding complications.

Medications:

Salbutamol Nebulization Q4 (short acting bronchodilator)

Medrol BID (glucocorticosteriod)

Symbicort (formoterol and budesonide)

O2 supplementation

Management Problem: Hypertension

Lifestyle Modification

Not at Goal Blood Pressure (<140/90 mmHg) (<130/80 mmHg for patients with diabetes or chronic kidney disease) JNC 7: Algorithm for **Initial Drug Choices** treatment of hypertension With Compelling Indications Without Compelling Idications Drug(s) for the compelling **Stage 1 Hypertension** stage 2 Hypertension indications (SBP 140-159 or DBP 90-99 (SBP >160 or DBP >100 mmHG) mmHG) Other antihypertensive Thiazide-type diuretics for 2-drug combination for drugs (diuretics, ACEI, ARB, most (usually thiazide type BB, CCB) as needed. most. May consider ACEI, ARB, BB, CCB, or diuretic and ACEI, or ARB, or combination. BB, or CCB). Not at Goal Blood Pressure

Optimize dosage or add additional drugs until goal blood pressure is achieved. Consider consultation with hypertension specialist.

Management of Hypertension

- From the algorithm we can deduce that the patient falls under stage 1 hypertension with usual BP of 130 and highest at 160, the patient is already on calcium channel blocker felodipine so the patient was managed by optimizing the dosage of felodipine.
- Bouts of hypertension was noted in the wards thus combination drugs were sometimes added as needed, these drugs included Losartan a ACE inhibitor and Amlodipine a long-acting calcium channel blocker.

Management Problem: PTB

- New patients with pulmonary TB should receive a regimen containing 6 months of rifampicin: 2HRZE/4HR (Strong/High grade of evidence)
- The 2HRZE/6HE treatment regimen should be phased out (Strong/High grade of evidence)

- Wherever feasible, the optimal dosing frequency for new patients with pulmonary TB is daily throughout the course of therapy (Strong/High grade of evidence)
- New patients with pulmonary TB may receive a daily intensive phase followed by three times weekly continuation phase [2HRZE/4(HR)3] provided that each dose is directly observed (Conditional/High or moderate grade of evidence)

Management of PTB

The patient was treated according to Recommendation 1.1 which states that,


New patients with pulmonary TB should receive a regimen containing 6 months' rifampicin: 2HRZE/4HR

The patient was able to complete the intensive phase of treatment which requires 2 months on HRZE and is on his continuing treatment for tuberculosis which is 4 months on HR (2/4months at time of admission)


Medications:

Rimactazid 450/400

COURSE IN THE WARDS



06.27.2011 (11th hospital day)



Prognosis

- 79% with secondary pneumothoraces and persistent air leaks: resolved air leaks by 14 days
- 5-year recurrence rate of 43% for secondary spontaneous pneumothorax
- Relationship of developing pneumothorax and smoking
- In COPD, survival rate is made using the BODE index

Follow-up on 7.12.11

↓ Breath sounds on left upper lung field

↑Tactile fremitus on left upper to mid left lung fields

Equal tactile fremitus in both basal lung fields

Hyperresonant on left lower lung fields, resonant in both upper upper lung fields

DRUGS

Symbicort 160/4.5 2 puffs 2x a day

Felodipine 10mg/tab

Rimactazid 100/450

Losartan 100mg/tab

